Paratek Pharmaceuticals
Paratek Pharmaceuticals is a privately held specialty biopharmaceutical company that develops and commercializes FDA-approved therapies for infectious disease, chronic rhinosinusitis, and (post-Radius merger) osteoporosis and endocrinology, serving U.S. healthcare providers via a dedicated field sales force and channel partners.
- Company typePrivate
- Founded1996
- HeadquartersBoston, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Paratek Pharmaceuticals does
Paratek Pharmaceuticals is a privately held specialty biopharmaceutical company founded in 1996, headquartered in King of Prussia, Pennsylvania, with an additional Boston office. It develops and commercializes innovative therapies for life-threatening infectious diseases and other difficult-to-treat conditions, anchored by NUZYRA (omadacycline), an FDA-approved once-daily oral and intravenous tetracycline-class antibiotic indicated for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Its portfolio also includes XHANCE (fluticasone propionate), a nasal spray using a proprietary Exhalation Delivery System (EDS) for chronic rhinosinusitis, and SEYSARA (sarecycline) for acne vulgaris, which is marketed in the U.S. by Almirall under a licensing arrangement. Following the March 2026 combination with Radius Health, the company added TYMLOS (abaloparatide) for osteoporosis and now operates across seven therapeutic areas.
The company generates revenue through U.S. pharmaceutical product sales distributed via standard wholesale, retail, and specialty pharmacy channels, supported by a dedicated field sales force that calls on primary care physicians and specialists to co-promote NUZYRA and XHANCE. Ex-U.S. commercialization is executed through regional partners, most notably Zai Lab for omadacycline in Greater China. Non-dilutive funding is provided through a BARDA Project BioShield contract valued at up to approximately $304 million supporting the development of NUZYRA for pulmonary anthrax under the FDA Animal Rule pathway. Additional revenue streams include licensing and royalty arrangements (e.g., SEYSARA via Almirall), investigator-initiated research grants, and medical affairs-supported continuing medical education programs.
The company was taken private in June 2023 by Novo Holdings and Gurnet Point Capital for approximately $462 million and subsequently acquired Optinose (XHANCE) for up to $330 million. In March 2026, Paratek completed a combination with Radius Health, financed through a $1.3 billion private placement led by Blackstone Credit & Insurance, with participation from Sixth Street, Oaktree Capital Management, Silver Point Capital, and Pharmakon Advisors, and equity backing from B-FLEXION Life Sciences. The combined company is projected to generate nearly $1 billion in annual revenue in 2026.
Paratek Pharmaceuticals firmographics
Firmographics- Name
- Paratek Pharmaceuticals
- Legal name
- Paratek Pharmaceuticals, Inc.
- Website
- https://paratekpharma.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Paratek Pharmaceuticals is a privately held specialty biopharmaceutical company that develops and commercializes FDA-approved therapies for infectious disease, chronic rhinosinusitis, and (post-Radius merger) osteoporosis and endocrinology, serving U.S. healthcare providers via a dedicated field sales force and channel partners.
- Ownership category
- akta.pro rank
Paratek Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Paratek Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Paratek Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
Revenue model
- Pharmaceutical Product Sales: Paratek generates revenue through the sale of FDA-approved pharmaceutical products, primarily NUZYRA (omadacycline) and XHANCE (fluticasone propionate). These are prescription medications commercialized in the United States through the company's own sales force and partnerships.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels8 records
Paratek Pharmaceuticals product offering
Product offeringCore offering
Paratek Pharmaceuticals develops, manufactures, and commercializes FDA-approved specialty pharmaceutical products focused on infectious diseases and other difficult-to-treat conditions. Its commercial portfolio includes NUZYRA (omadacycline), a tetracycline-class antibiotic for community-acquired bacterial pneumonia and skin infections; XHANCE (fluticasone propionate), a nasal spray using the proprietary Exhalation Delivery System for chronic rhinosinusitis; SEYSARA (sarecycline) for acne vulgaris marketed by Almirall; and TYMLOS (abaloparatide) for osteoporosis following the March 2026 Radius Health combination.
Product overview
Paratek Pharmaceuticals is a specialty pharmaceutical company with a multi-product commercial portfolio spanning infectious disease and other difficult-to-treat conditions. The core product portfolio consists of FDA-approved NUZYRA® (omadacycline), a tetracycline-class antibiotic for community-acquired bacterial pneumonia and skin infections; XHANCE® (fluticasone propionate), a nasal spray for chronic rhinosinusitis using an exhalation delivery system; and TYMLOS (abaloparatide), an osteoporosis therapy acquired through the 2026 Radius Health combination. The company also holds rights to SEYSARA® (sarecycline) for acne, marketed by Almirall. The combined company operates across seven therapeutic areas including infectious disease, endocrinology, and rheumatology, with projected annual revenue approaching $1 billion in 2026.
Differentiator
Problem solved
Functional benefit
Brands
- NUZYRA: FDA-approved tetracycline-class antibiotic for treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
- XHANCE
- TYMLOS
Products and services
- NUZYRA (omadacycline) FDA-approved once-daily oral and intravenous tetracycline-class antibiotic for treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. Also under development for pulmonary anthrax treatment via FDA Animal Rule and nontuberculous mycobacteria (NTM) pulmonary disease.
- XHANCE (fluticasone propionate) Prescription nasal spray approved by the U.S. FDA for the treatment of chronic rhinosinusitis with or without nasal polyps in adults. Uses the proprietary Exhalation Delivery System (EDS) designed to transport fluticasone deep into the nasal cavity targeting the site of inflammation.
- SEYSARA (sarecycline) FDA-approved tetracycline-derived antibiotic for treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Marketed by Almirall, LLC in the U.S. under a licensing/partnership arrangement.
- TYMLOS (abaloparatide) Osteoporosis therapy (abaloparatide) added to Paratek's commercial portfolio following the March 2026 combination with Radius Health. Part of the scaled multi-asset specialty pharmaceutical company spanning seven therapeutic areas including endocrinology and rheumatology.
Quantifiable outcome
- XHANCE 2023 FDA label expansion broadened eligible patient population 10-fold to approximately 10 million people
- +4 more outcomes
Companies that use Paratek Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles4 records
Paratek Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature5 records
Paratek Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered regional.
- Zai Lab (Shanghai) Co., Ltd.regionalParatek entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline (NUZYRA) for patients in Greater China. Zai Lab leverages its established commercial infrastructure in China to bring NUZYRA to patients in that region.
- Almirall, LLCregionalAlmirall, LLC markets SEYSARA (sarecycline) in the U.S. for the treatment of inflammatory acne vulgaris. Almirall owns the rights to sarecycline and is exploring partnership opportunities to develop and approve sarecycline in appropriate markets.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Paratek Pharmaceuticals competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Paratek Pharmaceuticals social profiles
Digital presenceParatek Pharmaceuticals compliance and trust
Trust signalCompliance2 records
Paratek Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paratek Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Paratek Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Paratek Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paratek Pharmaceuticals M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paratek Pharmaceuticals
What does Paratek Pharmaceuticals do?
Paratek Pharmaceuticals develops, manufactures, and commercializes FDA-approved specialty pharmaceutical products focused on infectious diseases and other difficult-to-treat conditions. Its commercial portfolio includes NUZYRA (omadacycline), a tetracycline-class antibiotic for community-acquired bacterial pneumonia and skin infections; XHANCE (fluticasone propionate), a nasal spray using the proprietary Exhalation Delivery System for chronic rhinosinusitis; SEYSARA (sarecycline) for acne vulgaris marketed by Almirall; and TYMLOS (abaloparatide) for osteoporosis following the March 2026 Radius Health combination.
Is Paratek Pharmaceuticals a public or private company?
Paratek Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.
When was Paratek Pharmaceuticals founded?
Paratek Pharmaceuticals was founded in 1996. It employs 251 to 500 people.
Where is Paratek Pharmaceuticals based?
Paratek Pharmaceuticals is headquartered in Boston, United States, in the North America region.
How does Paratek Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Paratek Pharmaceuticals have an API?
No public API is recorded for Paratek Pharmaceuticals.
What industry is Paratek Pharmaceuticals in?
Paratek Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 3254 and its SIC code is 2834.